Takeda Pharmaceutical Co. Ltd. announced results from the phase III ALTA-1L (ALK in lung cancer trial of BrigAtinib in 1st Line) trial, demonstrating that Alunbrig reduced the risk of disease progression or death, known as progression-free survival, as assessed by a blinded independent review committee, by more than 50 percent compared to crizotinib in adults with anaplastic lymphoma kinase-positive locally advanced or metastatic non-small cell lung cancer who had not received a prior ALK inhibitor.
Opioid use among cancer patients does not appear to be leading to the steep increase of overdoses seen in the general public, according to a study by Duke Cancer Institute researchers.
Even when they had good health insurance coverage, women with breast cancer reported having financial worries related to their care, and the vast majority said they preferred to know about treatment costs at the time of diagnosis.
Initial results from the first North American clinical study of CIMAvax-EGF show that this Cuban-developed immunotherapy is safe, well tolerated and worthy of further study. Principal Investigator Grace Dy, of Roswell Park Comprehensive Cancer Center, presented the findings at the International Association for the Study of Lung Cancer's 19th World Conference on Lung Cancer in Toronto, Canada.
IMV Inc. announced that investigators are evaluating IMV's lead candidate, DPX-Survivac, in combination with low dose cyclophosphamide and Merck's checkpoint inhibitor Keytruda (pembrolizumab), in patients with persistent or recurrent/refractory diffuse large B-cell lymphoma.
Vanderbilt-Ingram Cancer Center researchers have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies.
Crown Bioscience has completed a joint study with CARsgen Therapeutics and Shanghai Cancer Institute, demonstrating the elimination of gastric tumors in mice using CLDN18.2 targeting CAR-T cells. The work was recently published in the Journal of the National Cancer Institute.
Merck KGaA and Pfizer Inc. announced positive top-line results from the pivotal phase III JAVELIN Renal 101 study evaluating Bavencio (avelumab) in combination with Inlyta (axitinib), compared with Sutent (sunitinib) as initial therapy for patients with advanced renal cell carcinoma.
IMV Inc. said it has expanded its clinical program with a phase II basket trial evaluating its lead candidate, DPX-Survivac, in combination with low dose cyclophosphamide and Merck's anti-PD-1 therapy, Keytruda (pembrolizumab) in patients with select advanced or recurrent solid tumors.
Recently published results of a phase II clinical trial have shown the best outcomes to date for newly diagnosed older Hodgkin lymphoma patients treated with brentuximab vedotin given before and after doxorubicin, vinblastine and dacarbazine (AVD) chemotherapy, which is the standard of care.
